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The increasing antibiotic resistance of pathogenic bacteria calls for the development of alterna-
tive antimicrobial strategies. Possible approaches include the development of novel, broad-spec-
trum antibiotics as well as specific targeting of individual bacterial virulence factors. It is impos-
sible to decide currently which strategy will prove more successful in the future since they both 
promise different advantages, but also introduce diverse problems. Considering both approaches,
our laboratory’s research focuses on the evaluation of hemocidins, broad-spectrum antibacterial 
peptides derived from hemoglobin and myoglobin, and staphostatins, specific inhibitors of sta-
phopains — Staphylococcus aureus secreted proteases that are virulence factors regarded as pos-
sible targets for therapy. The article summarizes recent advances in both fields of study and
presents perspectives for further development and possible applications.
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The resistance of pathogenic microorganisms 
to currently known antibiotics is constantly increas-
ing due to a broad use of antimicrobials in medi-
cine, animal husbandry and agriculture. Although 
so far resistance of microorganisms to all approved 
compounds has rarely been noted, the number of 
such events will certainly increase with time (Mc-
Gahee & Lowy, 2000). If no preventive actions are 
taken, this will inevitably lead to a state that pre-
ceded the discovery of antibiotics, when efficient
treatment against bacterial infections was unavail-
able. The development of novel antibiotics and al-
ternative therapeutic strategies is therefore a burn-
ing necessity. 
Among many proposed strategies, studies 
on natural and artificial amphipathic peptides act-
ing on membranes of microorganisms have yielded 
promising results. Currently, more than 800 such 
peptide antibiotics have been described and some 
of them have already entered clinical trials. For 
several years our laboratory has conducted studies 
on hemocidins, antibacterial peptides derived from 
hemoglobin and myoglobin. We have characterized 
several naturally occurring and artificially derived
hemocidins with strong antimicrobial activity in 
the micromolar range (Mak et al., 2000). Both pro-
duction and application of hemocidins as drugs or 
preservatives were claimed in a patent (PL 187999). 
We are presently evaluating the physiological sig-
nificance of natural hemocidins in humans and try-
ing to increase the efficiency of already developed
peptides. 
Alternative antimicrobial strategies assume 
that specific virulence factors should be addressed
since bacteria are more likely to develop resistance 
to broad-range antibiotics. For example, Staphyloco-
ccus aureus is a bacteria whose virulence relies on 
production of a wide range of such factors (Novick, 
2000). Among others, extracellular proteases consti-
tute an important part of the bacteria’s weaponry. 
Recently, a novel family of very specific proteina-
ceous inhibitors of staphylococcal cysteine proteases 
has been described in our laboratory (Rzychon et 
al., 2003b). The achieved detailed structural charac-
terization makes it possible to design low molecu-
lar-mass molecules that could be effective against
staphylococcal infections (Dubin et al., 2003; Filipek 
et al., 2003; Rzychon et al., 2003a).  
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HEMOCIDINS — BROAD RANGE 
ANTIMICROBIALS
Proteolytic degradation of functional pro-
teins can lead to generation of peptides exhibiting 
a variety of biological activities (Karelin et al., 1998). 
The peptides are released during general non-spe-
cific proteolytic processes, a�er the maternal protein
substrates have fulfilled their primary physiologi-
cal roles. The functions of the released peptides are 
usually distinct from those of their precursors. Ad-
ditionally, in contrast to classical endocrine or para-
crine peptide hormones, the bioactivity of released 
peptide fragments is limited to the maintenance of 
local tissue homeostasis. 
The best characterized precursors of bioactive 
peptides include casein, albumin, lactoferrin, gluten, 
cytochrome c and, most importantly, hemoglobin 
(Ivanov et al., 1997). The la�er can be considered as
an exceptional example because the collection of he-
moglobin-derived bioactive peptides is particularly 
rich, comprising opioid-like, analgesic, hemopoietic, 
coronaro-constrictory, immunomodulatory, ACTH-
releasing ones and many others (Karelin et al., 1995). 
These peptides originate from both globin chains 
and the majority of them are not longer than 15 
amino acids. In certain circumstances, the peptides 
are generated from primary fragments of about 30 
amino acids already in erythrocytes.
A growing number of reports support a role 
of hemoglobin as a precursor of peptides able to kill 
microorganisms. The first communication document-
ing hemoglobin bactericidal properties appeared in 
1958 (Hobson & Hirsh, 1958), but more convincing 
evidence of the activity became only available in re-
cent years. Our laboratory contributed substantially 
to this development. In our early work concerning 
the issue (Mak et al., 2000) we demonstrated that re-
moval of heme is essential for the hemoglobin an-
tibacterial activity. The heme-divested and partially 
unfolded globin molecules were able to kill a variety 
of microorganisms at the half maximal lethal doses 
in the micromolar range. The same applies to my-
oglobin, whose activity is sustained a�er limited en-
zymatic or chemical digestion to approximately 50-
amino acid-long fragments. Further fragmentation 
(e.g., by trypsin) to shorter peptides results in nearly 
complete extinction of its antimicrobial properties.
We proposed the term hemocidins to name 
the bactericidal peptides derived from heme-con-
taining proteins. The term well describes the killing 
activity and points to the maternal proteins.
A representative peptide derived from horse 
myoglobin (amino acids 56–131) was chosen for a 
study on the mechanism of action of hemocidins 
(Mak et al., 2001). The peptide manifested pro-
nounced activity toward a variety of microorgan-
isms and, importantly, could be easily obtained 
by cyanogen-bromide digestion of myoglobin. We 
demonstrated that the activity of this cationic pep-
tide (net charge +10) was, to some extent, inhibited 
by high salt concentrations as well as by divalent 
cations, altogether showing the lack of its affinity to-
ward lipopolysaccharide. The experiments with pla-
nar bilayer membranes as well as circular dichroism 
spectra analysis showed that the 56–131 myoglobin 
peptide has a fully random structure in solution 
but folds rapidly upon contact with the negatively 
charged phospholipid membranes. The folding is as-
sociated with membrane integrity disruption. Moreo-
ver, the lack of discrete transmembrane conductance 
changes suggests that the peptide does not act as 
a channel-forming factor. These facts prompted us 
to hypothesize that hemocidins act in a carpet-like 
manner, characteristic for other α-helical antibacterial 
peptides (Oren & Shai, 1998). Following electrostati-
cally driven initial interaction with the membrane, 
the peptides form carpet-like clusters or plaques on 
the phospholipid bilayer, inducing destabilization of 
the membrane and, finally, its disruption.
Our results concerning the high potential of 
hemoproteins for generation of antimicrobial pep-
tides were recently confirmed by another research
group (Parish et al., 2001). We propose that the po-
tential is primarily associated with the abundance in 
hemoproteins of amphipathic α-helical domains of a 
characteristic bipolar distribution of charged and hy-
drophobic amino-acid residues. In this way the he-
moprotein-derived fragments to some extent imitate 
important features of classical, gene-encoded peptide 
antibiotics.
The majority of the experiments mentioned 
above were performed in vitro, using either synthet-
ic peptides or the products of enzymatic digestion of 
maternal proteins. However, taking into considera-
tion the abundance of hemoproteins in animals and 
humans, it is of special interest to evaluate the role 
of hemocidins in the innate defense mechanisms 
against infections. The first communication that doc-
umented the presence of hemocidins in organisms 
referred to the bactericidal bovine hemoglobin frag-
ment found in the gut of a tick (Fogaca et al., 1999). 
A similar peptide originating from rabbit hemoglob-
in was discovered recently (Nakajima et al., 2003), 
also in a tick’s gut. The authors of both papers sug-
gested that the parasite uses the host protein as a 
protective antimicrobial agent in its own digestive 
tract. Another report on naturally occurring hemoci-
dins concerned peptides isolated from homogenates 
of human placenta and from lysed erythrocytes 
(Liepke et al., 2003). One of those peptides was iden-
tified as a fragment of fetal γ-hemoglobin while a
second one was from β-hemoglobin. Both peptides 
killed Gram-negative and Gram-positive bacteria in 
concentrations of tens µmole/l. Unfortunately, the 
la�er work was performed on tissue homogenates
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prepared without the addition of protease inhibitors 
and therefore it remains unclear whether the isolat-
ed hemocidins were true peptide constituents of the 
analyzed tissues or rather were artifacts resulting 
from the purification procedure. Likewise, the physi-
ological significance of both isolated hemocidins re-
mains unknown.
In our recent communication we have docu-
mented that hemocidins are abundant in normal 
female menstrual discharge (Mak et al., 2004). Our 
work comprised a thorough analysis of peptide frac-
tions isolated from the plasma of vaginal discharge 
of three healthy nulliparous women by high-per-
formance liquid chromatography, automatic sequenc-
ing and mass spectrometry. Although the obtained 
peptide maps varied between the three subjects, the 
phenomenon seems natural and most probably re-
flects the complexity of individual vaginal ecosys-
tem. We have identified 45 peptides altogether in all
patients, 44 of which originated from hemoglobin, 
mainly from the N-terminal part of α-globin. All the 
isolated peptides demonstrated bactericidal activity 
toward Escherichia coli. Detailed screening of the an-
timicrobial action toward a variety of Gram-negative 
and Gram-positive bacteria was performed using 
two synthetic peptides identical to those found in 
menstrual blood. The estimated minimal inhibitory 
concentrations (MIC doses) for those peptides were 
between 27 and 293 µM. However, no killing activ-
ity toward the yeast Candida albicans was observed 
at the highest applied concentration (300 µM).
It is clear that specific conditions in the vagina
during menstrual bleeding strongly favor the gener-
ation of hemocidins. Since the pH of the uterine cav-
ity is neutral, hemoglobin is probably released from 
erythrocytes in the low pH of the vagina. Low pH 
is also a factor that causes dissociation of the hemo-
globin molecule as well as disruption of some hy-
drogen bonds within the globin molecule. Partial de-
naturation facilitates the action of proteases. Indeed, 
it is noteworthy that besides the lysed functional 
layer of the endometrium, mucus, blood plasma and 
blood cells, the menstrual discharge contains also 
significant amounts of proteolytic enzymes, mainly
matrix metalloproteinases (MMPs) and leukocyte 
proteases (Salamonsen & Lathbury, 2000; Salam-
onsen et al., 2002). We believe that these proteases, 
among others, are responsible for liberation of he-
mocidins. 
From the medical point of view, one of the 
most important features of menstrual hemocidins is 
their high activity toward E. coli. Urinary tract colo-
nization by this microorganism represents an impor-
tant health problem for women. We hypothesize that 
the lack of hemocidins may underlie frequent vagi-
na colonization by E. coli in postmenopausal women 
(Pabich et al., 2003). Li�le is known about the main-
tenance of vaginal homeostasis during menstruation. 
We assume that the described vaginal hemocidins 
are an important part of the nonspecific bactericidal
mechanisms that support human vaginal homeosta-
sis during physiologic menstrual bleeding. 
The work described above on the bactericid-
al menstrual hemoglobin-derived peptides clearly 
suggests that hemocidins constitute a new and sig-
nificant mechanism supporting classical, well-known
mechanisms of innate unspecific immunity against
infections. However, these discoveries do not ex-
haust the interesting theme of vaginal homeostasis. 
We are presently working on genital secretions of 
women with infections (vaginosis) and on vaginal 
discharges a�er birth (lochia), in hope of obtain-
ing an insight into the mechanisms of formation 
of vaginal hemocidins as well as on the role of the 
peptides in the pathophysiology of the female uro-
genital tract. We also plan to investigate other avail-
able clinical material that can possibly contain he-
mocidins. The research will comprise analysis of the 
peritoneal dialysis fluid obtained from patients with
kidney failures, the discharge from wounds, fluids
from post-surgery caves, and others. We hope that 
our research will allow us to obtain comprehensive 
answers for principal questions concerning hemoci-
dins.
STAPHOSTATINS — SELECTIVE TARGETING OF 
VIRULENCE FACTORS
As an alternative to the development of 
broad-range antibiotics, which the bacteria are likely 
sooner or later to gain resistance to, due to the great 
selective pressure exerted by their use, targeting of 
specific virulence factors has been proposed. Such
strategy imposes the need of developing a great 
number of different agents specific against only a 
narrow spectrum of pathogens, limited to species or 
even particular strains. However, resistance is less 
likely to develop in such a setup and the known ad-
verse effects of broad spectrum antibiotics on natu-
ral microflora may be avoided. Moreover, such a
strategy greatly broadens the number of available 
targets, which, in connection with high-throughput 
screening techniques, may facilitate a faster devel-
opment of agents suitable for therapeutic purposes 
against at least some bacteria. 
Part of the research conducted at our labora-
tory is focused on Staphylococcus aureus, one of the 
most versatile and dangerous human pathogen. In 
view of the increasing antibiotic resistance of this 
species, screening for suitable targets and develop-
ment of novel antistaphylococcal compounds is a 
burning necessity (McGahee & Lowy, 2000). The 
virulence factors of S. aureus, targets suitable for 
the strategy described above include, amongst oth-
ers, a spectrum of secreted proteases. Staphylococci 
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secrete a range of serine proteases (SspA, six ho-
mologous Spl proteases, epidermolytic toxins A and 
B), cysteine proteases (staphopains A and B) and a 
metalloprotease (aureolysin) (Dubin, 2002). The im-
portance of some of these enzymes for the virulence 
of the bacterium has been demonstrated in different
infection models, although the evidence seems con-
tradictory at some points and the topic still awaits 
thorough investigation.
Different protease and protease expressions
regulating systems knock-out strains evaluated in 
animal infection models have produced a some-
what confusing picture as to the role of particular 
enzymes and the overall secreted proteolytic activ-
ity in staphylococcal virulence. Nevertheless, despite 
the fact that the evaluation of individual strains was 
done in various models and  a systematic study en-
compassing knock-outs of all known proteases in a 
single model is lacking, some encouraging reports 
have been produced. Below, the current state of in-
vestigation on the role of staphylococcal proteases in 
virulence determination is briefly summarized.
A clear demonstration of a role of a particular 
proteolytic enzyme in staphylococcal virulence was 
possible only in the case of epidermolytic toxins in 
staphylococcal scalded-skin syndrome (Prévost et 
al., 1991; Redpath et al., 1991). Reportedly, the viru-
lence of V8 serine protease (sspA–) and serine pro-
tease-like operon (spl–) knock-outs was not affected
significantly in murine abscess infection model or
a�er intraperitoneal injection, respectively (Reed
et al., 2001; Rice et al., 2001). Moreover, the former 
knock-out showed even slightly enhanced virulence. 
In contrast, the virulence of the same V8 deficient
strain was decreased in a Caenorhabditis elegans mod-
el (Sifri et al., 2003).  Furthermore, the virulence of 
a strain deficient in the V8 protease and staphopain
B (sspABC–) was markedly reduced in comparison 
to the wild type in several different mouse models
(Coulter et al., 1998). The above data points at sta-
phopain B as the main virulence determinant among 
secreted proteases. Further observations supporting 
this claim were recently published by Shaw and 
colleagues (2004). The virulence of four knock-out 
strains of main staphylococcal extracellular proteas-
es was evaluated in a murine subcutaneous skin ab-
scess model. The virulence of metalloprotease- (aure-
olysin) and one of the cysteine proteases (staphopain 
A)-deficient strains was not affected while knock-
outs of another cysteine protease (staphopain B) and 
a serine protease (SspA) were significantly affected.
Since the la�er knock-out also lacks the coexpressed
staphopain B, while the staphopain B-deficient strain
expresses the SspA protease, these data again point 
to staphopain B as the main virulence determinant. 
However, unambiguous demonstration of the fact 
awaits studies in diverse genetic backgrounds and a 
comparative, over view of different animal models.
Further complicating the presented picture, the sarA 
regulatory locus mutant overproducing a number of 
proteases showed a decreased virulence in a rabbit 
endocarditis model (Cheung et al., 1994). However, 
agr null mutants, characterized by a profound defect 
in overall exoprotein production, showed a highly 
diminished virulence in a murine septic arthritis 
model (Abdelnour et al., 1993).
Recently, our laboratory has characterized a 
family of specific staphylococcal cysteine protease
inhibitors (Rzychon et al., 2003b). In the light of the 
above presented data on staphopain B the proteins 
may provide suitable leading structures for the de-
velopment of low molecular mass therapeutic ana-
logs.
Staphostatins constitute a novel family of 
specific proteinaceous inhibitors of staphylococcal
cysteine proteases — staphopains. Although the en-
zymes belong to clan CA of papain-like proteases, 
staphostatins inhibit exclusively the staphylococcal 
enzymes and not other clan members tested. Such 
specificity is of great value in the development of
therapeutic molecules if it could be preserved in low 
molecular mass compounds, since various CA-clan 
peptidases act in great many physiological processes, 
making cross-inhibition unacceptable. The specificity
of staphostatins is not only limited to staphopains 
but is even stricter since S. aureus staphostatin A in-
hibits only S. aureus staphopain A while staphostatin 
B inhibits only staphopain B (Rzychon et al., 2003b). 
In each case the inhibitor and the target enzyme are 
encoded in one operon, suggesting that the inhibi-
tors were designed by nature to inhibit only their 
target proteases. Nevertheless, staphopains are ex-
tracellular enzymes and staphostatins reside intra-
cellularly. Clues to the role of the la�er inhibitors
became available only recently with transgenesis 
and knock-out studies. Staphopains are toxic to E. 
coli when expressed ectopically, while co-expression 
with staphostatins may be easily achieved (Wlady-
ka et al., 2005). Moreover, an S. aureus staphostatin 
B knock-out strain exhibits decreased growth rate 
(personal communication). The above data clearly il-
lustrate the protective role of staphostatins towards 
the cytoplasm against ectopically expressed (E. coli) 
or misdirected (S. aureus) staphopains, and a�est to
the deleterious effects of those staphylococcal viru-
lence factors. 
Despite the quite recent discovery of the sta-
phostatin family a multitude of structural data are 
available on the inhibitors. Structures of S. aureus 
staphostatins A and B have been solved as well as 
the structure of a staphopain B–staphostatin B com-
plex (Dubin et al., 2003; Filipek et al., 2003; Rzychon 
et al., 2003a). The former works demonstrated that 
staphostatins share a fold similar to lipocalins, how-
ever, no functional similarities were demonstrated. 
The la�er structure made it possible to pinpoint the
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staphostatin active site and to infer its mode of ac-
tion. Unlike the previously known cysteine protease 
inhibitors, the staphostatin polypeptide chain spans 
the active site of the protease in a manner similar 
to the substrate, rather resembling the “standard 
mechanism” of serine proteases. The inhibitor es-
capes cleavage due to the distinct disposition of the 
P1 glycine residue. The la�er was confirmed by site
directed mutagenesis, since replacement of P1 with 
other amino acids converted the inhibitor into a sub-
strate. Despite the wealth of structural information 
described, the mechanism of the strict specificity de-
termination remains unresolved. Studies are ongoing 
in our group to elucidate biology of this important 
issue of staphostatins. Along, low molecular mass 
compounds mimicking the staphostatin inhibitory 
properties are being evaluated.
PERSPECTIVES
For many years a�er the antibiotics became
widely available it seemed that the mankind has 
finally won its struggle against pathogenic micro-
organisms. Adding splendor to the glorious victory, 
the price to pay, comprising minor and mostly pre-
dictable side effects, was very low. Unfortunately,
with time, the almost forgo�en pathogens have re-
covered, acquiring resistance to the antimicrobials. 
Effective derivatives were and are still being devel-
oped, but the microorganisms even faster overcome 
their effects. We are still, fortunately, the winning
side but the situation gets gradually worse. It is al-
ready obvious and widely accepted that if no pre-
ventive measures are taken we will sooner or later 
again face the threat of uncurable bacterial infec-
tions. Multiantibiotic therapies, increased responsi-
bility of therapeutists and patients and decreasing 
the unnecessary utilization may greatly prolong the 
period needed for the bacteria to develop resistance 
and allow sufficient time to develop novel strate-
gies. However, to know and to use the knowledge 
is worlds apart.
Since it is already obvious that the currently 
known antibiotics and possible derivatives will soon-
er or later lose their efficiency, the search for novel
targets and chemicals is of great value. Two possible, 
divergent approaches were described here together 
with their anticipated advantages and drawbacks. 
The antibacterial peptides targeting the membrane, 
with their observed diversity and proven effective-
ness, provide a very promising pool to search in. 
The already seen obstacles include the impossibility 
of oral application (digestive tract proteases; perme-
ability) and possible toxicity against the host cells at 
higher concentrations. Nevertheless, such peptides 
might prove very suitable for topical administra-
tion. Nothing is known about natural resistance to 
such agents but since the mechanisms would have 
to be much more complicated (eg., cell membrane 
composition changes) than those utilized against the 
currently used antibiotics, it seems less likely to de-
velop soon.
Unlike to the former broad-range strategy 
the second one proposed assumes the development 
of compounds targeting specific virulence factors
produced by a narrow range of pathogens. Most 
probably targeting of several factors by different
compounds will be necessary during a single treat-
ment. In such a setup the resistance is less likely to 
develop, as in multiantibiotic strategies, the natural 
microflora will not be affected and no inter-species
resistance transfer will be possible. While, the de-
velopment of such multicompound strategies seems 
presently very unlikely, due to the enormous effort
and funds necessary to develop even single-com-
pound novel drugs, the evolving high-throughput 
screening and evaluation techniques might prove 
more suitable in a setup where multiple, instead of 
single, targets are tested in a more randomized man-
ner to find chemicals effective only against a small
subset of those.
Whichever setup is considered, the progress 
in the industry will only be facilitated by basic stud-
ies. A lot remains to be done in learning the proper-
ties of antibacterial peptides, especially in vivo, and 
evaluating the importance of different virulence fac-
tors of bacteria. Such studies will be continued in 
our laboratory and by scientists around the world 
in the forthcoming years and some results further 
utilized by the industry will surely contribute to the 
further improvement in our struggle against micro-
bial pathogens.
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